MedTrace Logo

Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)

NCT04907279 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-04-20

No results posted yet for this study

Summary

To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its clinical use in the proposed patient population, including time to discharge, efficacy, safety, tolerability, and patients' satisfaction.

Conditions

Interventions

DRUG

Aripiprazole Once-Monthly (AOM)

Dosage and frequency of AOM administration individualized for each study participant in accordance with investigators' clinical judgment.

Sponsors & Collaborators

  • Lundbeck Canada Inc.

    collaborator INDUSTRY

  • Otsuka Canada Pharmaceutical Inc.

    lead INDUSTRY

Principal Investigators

  • Francois Therrien, Pharm.D. · Otsuka Canada Pharmaceutical Inc.

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-12-31
Completion
2023-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04907279 on ClinicalTrials.gov